Modern treatment methods have led to major improvements in survival rates of children with Wilms' tumor. Multimodality therapy including nephrectomy and chemotherapy results in long-term survival of 90% of children with stage I and II favorable histology Wilms' tumor while treatment with nephrectomy, radiation therapy and three-drug chemotherapy with vincristine, actinomycin D and doxorubicin results in long-term relapse-free survival of 85 % of patients with stage III and IV, favorable histology Wilms' tumor. Clinical and pathological features have not allowed accurate identification of those patients destined to relapse within each stage. This identification is necessary to allow administration of more aggressive treatment regimens to the small group of patients who are destined to relapse without exposing those patients with an excellent prognosis using current treatment methods to the additional risk associated with more aggressive chemotherapeutic regimens. Biological variables have been identified and prospectively evaluated in children with other malignancies and have been found to aid in the identification of children at greater risk of recurrence of their disease. We propose to evaluate 250-300 children with Wilms' tumor to determine if (1) loss of heterozygosity for chromosomal regions 11p13, 11p15, 16q or 1p, (2) duplication of chromosome region 1q and/or (3) absent expression of the WT1 gene predicts significantly worse two-year relapse-free survival in children with Wilms' tumor; (4) to determine whether Wilms' tumors which contain a mutation at one or both alleles of WT1 gene are associated with a clinically worse prognosis; (5) to determine whether nuclear morphometric characteristics can be identified which accurately discriminate patients with favorable histology tumors who have an adverse prognosis with currently available treatment methods. The results of this research may allow more accurate identification of Wilms' tumor patients whose prognosis is poor with current therapeutic methods. More aggressive therapy may then be evaluated in this group of patients in the future to determine if such therapy improves the prognosis for these patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01CA060114-01
Application #
3550086
Study Section
Special Emphasis Panel (SRC (68))
Project Start
1993-07-15
Project End
1996-06-30
Budget Start
1993-07-15
Budget End
1994-06-30
Support Year
1
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
City
Buffalo
State
NY
Country
United States
Zip Code
14263
McDonald, J M; Douglass, E C; Fisher, R et al. (1998) Linkage of familial Wilms' tumor predisposition to chromosome 19 and a two-locus model for the etiology of familial tumors. Cancer Res 58:1387-90
Huff, V (1998) Wilms tumor genetics. Am J Med Genet 79:260-7
Huff, V; Amos, C I; Douglass, E C et al. (1997) Evidence for genetic heterogeneity in familial Wilms' tumor. Cancer Res 57:1859-62
Grundy, P; Telzerow, P; Moksness, J et al. (1996) Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis. Med Pediatr Oncol 27:429-33
Gunning, K B; Cohn, S L; Tomlinson, G E et al. (1996) Analysis of possible WT1 RNA processing in primary Wilms tumors. Oncogene 13:1179-85
Beckwith, J B; Zuppan, C E; Browning, N G et al. (1996) Histological analysis of aggressiveness and responsiveness in Wilms' tumor. Med Pediatr Oncol 27:422-8
Huff, V; Jaffe, N; Saunders, G F et al. (1995) WT1 exon 1 deletion/insertion mutations in Wilms tumor patients, associated with di- and trinucleotide repeats and deletion hotspot consensus sequences. Am J Hum Genet 56:84-90
Gearhart, J P; Willmann, J R; Beckwith, J B et al. (1995) Nuclear morphometric analysis of metastasis in Wilms' tumor after multimodal therapy: comparison with primary tumor. Urology 45:119-23
el-Naggar, A K; Hurr, K; Batsakis, J G et al. (1995) Sequential loss of heterozygosity at microsatellite motifs in preinvasive and invasive head and neck squamous carcinoma. Cancer Res 55:2656-9
Szabo, J; Heath, B; Hill, V M et al. (1995) Hereditary hyperparathyroidism-jaw tumor syndrome: the endocrine tumor gene HRPT2 maps to chromosome 1q21-q31. Am J Hum Genet 56:944-50

Showing the most recent 10 out of 11 publications